Oxidative stress has been reported to play a role in melasma pathophysiology. The objective of the study is to compare oral superoxide dismutase (GLISODin) to placebo, in combination to sunscreen to decrease melasma severity.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Enrollment
40
CHU de Nice - Dermatology
Nice, Alpes-Maritime, France
Severity of melasma
Change from Baseline of the Modified Melasma Area and Severity Index (mMASI) total score at 12 months. The MASI is 0 à 24 : Front 0.3(D)(A)+ right malar 0.30(D)(A)+ left malar 0.30(D)(A)+ chin 0.1(D)(A)
Time frame: At baseline and at 12 weeks
Quality of life of patient: VAS (Visual Analog Scale)
Change from Baseline of quality of life at 12 months (Visual Analog Scale with a graduation from 0 to 10)
Time frame: At baseline and at 12 weeks
Satisfaction of the patients: VAS (Visual Analog Scale)
Change from Baseline of satisfaction of the patients total score at 12 months (Visual Analog Scale with a graduation from 0 to 10)
Time frame: At baseline and at 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.